**BACKGROUND:** Infantile hemangioma (IH) is a common benign tumor, which arises in 1.7% of newborns in Japan. They are often treated at the field of plastic and reconstructive surgery. IH can cause disfigurement and/or lead to serious complications depending on their specific locations, for example, disturbing vision, airway at perioral area. It has been reported that 12%--24% of IH patients have any complications and require medical treatment. In our country, oral propranolol treatment for IH application has only been covered under the national health insurance system since 2016. However, there have been few reports about the efficacy of oral propranolol against IH in Japanese patients. In this study, we examined the effectiveness and side effects of oral propranolol treatment for IH conducted at our hospital.

**METHODS:** This study examined 12 cases of IH that were diagnosed between January 2017 and August 2018. All 12 patients were treated with oral propranolol (due to ulceration, a functional disorder, or cosmetic issues or risks of tumor-related bleeding). Sex, age at the onset, the affected site, clinical type, age at the initial administration of propranolol, the reason for propranolol treatment, the hospitalization period for initiation of propranolol treatment, the duration of propranolol treatment, the treatment response (tumor reduction, color change, regression, or softening; rated as excellent, good, or fair), and side effects were evaluated.

**RESULTS:** The 12 patients included 3 males and 9 females. The face and trunk were affected in 8 and 3 cases, respectively. Nine patients had superficial IH. The patients' mean age at the start of propranolol treatment was 3.7 months (range, 1--8 months), and the mean duration of hospitalization was 4.5 days (range, 4--7 days). Oral propranolol was continued for 12.4 months on average. All of the IH reduced in size after the propranolol treatment. Nine, 2, and 1 cases exhibited excellent, good, and fair responses, respectively. There were no side effects (0 of 12 cases). Six patients were treated with a dye laser. Two of them underwent dye laser treatment while being treated with propranolol because of the rapid growth of their IH. In 3 patients, a dye laser was used to alter the color of the IH after the propranolol treatment.

**CONCLUSION:** Oral propranolol treatment successfully reduced the size of the tumor in all cases. The success rate (excellent or good) was 91.7% (11 of 12 cases). In this study, no patients have side effects. However, serious side effects have been reported. Therefore, further accumulation of Japanese IH cases is expected. It is important to observe patients carefully after the initiation of propranolol treatment and to monitor their vital signs and blood sugar levels. Finally, oral propranolol treatment is recommended for IHs, especially which disturb the patient's vision, airway, eating at perioral sites, or expands rapidly, or which is not feasible in laser irradiation, for example, IH at hairy area or IH with ulceration.
